Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
基本信息
- 批准号:8212753
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-10-01 至 2014-09-30
- 项目状态:已结题
- 来源:
- 关键词:AbscessAdjuvantAdverse effectsAlhydrogelAntibioticsAntibodiesAntibody AffinityAntigen-Antibody ComplexAntigensAutologousAutopsyB-Lymphocyte EpitopesB-LymphocytesBacillus anthracisBiological AssayBody WeightCD4 Positive T LymphocytesChemistryCombined VaccinesCommunitiesCutaneousDataDepositionDevelopmentEpitopesEvaluationGoalsHelper-Inducer T-LymphocyteHematologyHistopathologyHospitalsHumanImmuneImmune SeraImmune responseImmunityIn VitroIndividualInfectionInjuryLeadLifeLinear RegressionsLinkMeasuresMediatingModelingMonitorMorbidity - disease rateMusN-terminalNursing HomesOrganOryctolagus cuniculusPeptide VaccinesPeptidesPeripheral Blood Mononuclear CellPhenolsPneumoniaPopulationProtocols documentationQualifyingResistanceSafetyScreening procedureSocietiesStaphylococcus aureusT-Lymphocyte EpitopesTestingToxic effectToxinVaccinationVaccinesVancomycinVeteransVirulence FactorsVirulentWarWorkalpha Toxincandidate validationcytokinecytotoxicimmunogenicityin vitro Assayin vivolymph nodesmethicillin resistant Staphylococcus aureusmortalitymouse modelneutralizing antibodynonhuman primatenovel strategiespeacepre-clinicalpreventprotective efficacyprotein aminoacid sequenceprototypepublic health relevanceresearch clinical testingtoolvaccine candidatevaccine developmentvaccine efficacyvaccine safetyvalidation studies
项目摘要
DESCRIPTION (provided by applicant):
Staphylococcus aureus has become a multifaceted threat faced in our hospitals, our nursing homes, and increasingly, in our communities. In particular, methicillin-resistant S. aureus (MRSA) has been an increasing problem in each of these venues, and resistance to other antibiotics, including varying degrees of resistance to vancomycin, is increasingly complicating management of S. aureus infections. The goal of this project is to develop epitope-specific vaccines targeting alpha toxin and the phenol-soluble modulins (PSMs), which are two critical virulence factors for S. aureus, for use in preventing S. aureus infections. Antibody neutralizing determinants will be identified in alpha toxin and the PSMs through screening of peptide sequences in vivo in the mouse model. Multiple antigenic peptides (MAPs) containing universal heterologous helper T cell epitopes or autologous helper T cell epitopes identified from alpha toxin, colinearly-linked to the neutralizing B cell determinants, will then be screened for efficacy in the murine pneumonia and cutaneous abscess challenge models employing virulent alpha toxin- and PSM-producing MRSA. Immune correlates of protection, including antibody and toxin neutralizing titer and antibody affinity, will be assessed in vitro and used to model vaccine-related efficacy in preventing morbidity and mortality from S. aureus infections in mice. Following a rigorous evaluation of vaccine safety in the murine model, MAP vaccines will be validated for immunogenicity in outbred rabbits using human use adjuvants, and the rabbit antisera will be evaluated for protective efficacy using passive transfer protocols in the mouse models of S. aureus infection, as a prelude to further clinical testing in nonhuman primates.
PUBLIC HEALTH RELEVANCE:
Staphylococcus aureus has become a multifaceted threat that confronts us in war and peace. It is present on the battlefield, in our hospitals, our nursing homes, and our communities, turning lesser injuries and illnesses into life-altering catastrophes. It is becoming increasingly resistant to our antibiotics, and is escaping our control measures. The goal of this project is to provide the VA, and society at large, with a new tool and a new approach for countering the human and financial burden of S. aureus infections by developing a vaccine that targets two critical virulence factors, alpha-toxin and the phenol-soluble modulins. This work may lead to a safe and effective virulence factor-specific S. aureus vaccine that could broadly benefit the veteran and non-veteran population, and may facilitate the development of other virulence factor vaccines.
描述(由申请人提供):
金黄色葡萄球菌已成为我们的医院、疗养院以及越来越多的社区面临的多方面威胁。特别是,耐甲氧西林金黄色葡萄球菌 (MRSA) 在这些场所中已成为一个日益严重的问题,而对其他抗生素的耐药性,包括对万古霉素的不同程度的耐药性,使金黄色葡萄球菌感染的管理变得越来越复杂。该项目的目标是开发针对 α 毒素和酚溶性调节蛋白 (PSM)(金黄色葡萄球菌的两个关键毒力因子)的表位特异性疫苗,用于预防金黄色葡萄球菌感染。通过在小鼠模型中筛选体内肽序列,将在 α 毒素和 PSM 中鉴定抗体中和决定簇。然后,将筛选含有从 α 毒素中鉴定出的通用异源辅助 T 细胞表位或自体辅助 T 细胞表位、与中和 B 细胞决定簇共线连接的多种抗原肽 (MAP),以评估其在使用产生剧毒 α 毒素和 PSM 的 MRSA 的小鼠肺炎和皮肤脓肿攻击模型中的功效。保护的免疫相关性,包括抗体和毒素中和滴度和抗体亲和力,将在体外进行评估,并用于模拟预防小鼠金黄色葡萄球菌感染发病和死亡的疫苗相关功效。在对小鼠模型中的疫苗安全性进行严格评估后,将使用人用佐剂在近交系兔子中验证 MAP 疫苗的免疫原性,并将在金黄色葡萄球菌感染的小鼠模型中使用被动转移方案评估兔抗血清的保护功效,作为在非人灵长类动物中进一步临床测试的前奏。
公共卫生相关性:
金黄色葡萄球菌已成为我们在战争与和平时期面临的多方面威胁。它存在于战场、我们的医院、我们的疗养院和我们的社区,将较轻的伤害和疾病变成了改变生活的灾难。它对我们的抗生素的抵抗力越来越强,并且正在逃避我们的控制措施。该项目的目标是通过开发针对两种关键毒力因子(α-毒素和酚溶性调节蛋白)的疫苗,为退伍军人管理局和整个社会提供一种新工具和新方法,以应对金黄色葡萄球菌感染造成的人力和经济负担。这项工作可能会产生一种安全有效的毒力因子特异性金黄色葡萄球菌疫苗,使退伍军人和非退伍军人群体广泛受益,并可能促进其他毒力因子疫苗的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kemp Bailey Cease其他文献
Kemp Bailey Cease的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kemp Bailey Cease', 18)}}的其他基金
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
- 批准号:
8391150 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
- 批准号:
8597331 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
- 批准号:
8045558 - 财政年份:2010
- 资助金额:
-- - 项目类别:
ADJUVANT STRATEGIES USING T CELL HELP ENHANCER PEPTIDES
使用 T 细胞帮助增强肽的佐剂策略
- 批准号:
3547529 - 财政年份:1989
- 资助金额:
-- - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
-- - 项目类别: